Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Sepura, ReNeuron, Angel Bio ...

Wed, 16th May 2012 15:18

Sepura, the developer and supplier of TETRA digital radios, has acquired 3T Communications, a supplier of TETRA infrastructure, for an initial cash consideration of 8m euros. The final price could increase by up to 5m euros, depending on 3T's trading performance. Austrian firm 3T designs and implements small to mid size TETRA systems predominantly for the commercial sector, including enterprise customers such as Shell, RWE, Bayer and BMW. The acquisition is expected to be earnings enhancing to Sepura for the current financial year and beyond.Electrical component supplier e2v technologies has agreed the sale of its non-core businesses, for a total cash consideration of £14.7m, to a newly formed company, SGX Sensortech, backed by Baird Capital Partners. The non-core businesses comprise: e2v Scientific Instruments, based in High Wycombe; the industrial gas sensing business based at e2v's Chelmsford facility; and e2v micro-sensors SA based in Neuchetel Switzerland. They provide a range of professional sensing products for x-ray spectroscopy and gas sensing for automotive and environmental safety applications.ReNeuron, the Surrey based stem cell developer, has signed a cell manufacturing contract with Angel Biotechnology, a bio-pharmaceutical contract manufacturer, to perform drug product manufacturing services as part of the PISCES Phase I clinical trial of ReNeuron's ReN001 stem cell therapy for stroke victims. The remaining dose cohorts in the current study are expected to complete treatment within the next twelve months, and the company maintains its belief that the study will be ready for application for phase two during the course of next year.Arden Partners, an institutional stockbroking company, has revealed that trading during the six months ended April 30th has been better than anticipated with revenues and profitability ahead of budget. Since the year end the company has increased the number of brokerships to 34 and this number is expected to grow in the medium term. The average market capitalisation of its clients is now £195m. Performance in the second half of the year will depend on market conditions, which given the situation in Europe dictates a need for some caution, the firm warned. The company intends to return to the dividend list from the interim period. Yell, a digital services provider, has acquired Moonfruit, the UK's leading DIY website and online shop builder, for £18m, a part of its programme of creating a local eMarketplace. The firm was purchased using Yell's existing cash reserves. Retention bonuses of as much as £5.2m will be paid to key Moonfruit management after two years, provided that they remain exclusively employed by Yell. In a statement Yell said: "The deal is a significant move in Yell's ongoing transformation from its established position in providing print and online advertising for small and medium-sized enterprises (SMEs) to become a leader in the emerging local eMarketplace." Source BioScience, a diagnostics and genetic analysis business, has enjoyed a period of sustained growth and development during the first three months of 2012. Revenue saw a double digit percentage increase compared with the same period last year, boosted by significant progression of LifeSciences' DNA sequencing services and Healthcare's cervical cancer screening business. Trading was in line with management expectations and the group remains in a robust financial position with £1.7m of cash at the end of March 2012 (31 December 2011: £1.1m).NR
More News
10 Sep 2020 16:01

UK TRADING UPDATE SUMMARY: Prime People Hurt As Covid Hits Job Market

UK TRADING UPDATE SUMMARY: Prime People Hurt As Covid Hits Job Market

Read more
3 Sep 2020 16:06

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
12 Aug 2020 13:35

IN BRIEF: ReNeuron Adds Obotritia Rep To Board; Names New Chair

IN BRIEF: ReNeuron Adds Obotritia Rep To Board; Names New Chair

Read more
31 Jul 2020 16:22

ReNeuron gets patent allowance in the US

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Friday that the US Patent and Trademark office (USPTO) has completed its examination of its application titled 'phenotype profile of human retinal progenitor cells', and has issued a notification of allowance for the issue of a patent.

Read more
31 Jul 2020 11:28

UK WINNERS & LOSERS SUMMARY: Pets At Home Up 15% On June Sales Bounce

UK WINNERS & LOSERS SUMMARY: Pets At Home Up 15% On June Sales Bounce

Read more
29 Jun 2020 20:39

IN BRIEF: ReNeuron Posts Encouraging Data On Eye Condition Treatment

IN BRIEF: ReNeuron Posts Encouraging Data On Eye Condition Treatment

Read more
25 Jun 2020 14:55

IN BRIEF: ReNeuron Signs Exosome Research Collaboration With US Firm

IN BRIEF: ReNeuron Signs Exosome Research Collaboration With US Firm

Read more
25 Jun 2020 11:22

ReNeuron Group inks research evaluation deal with US firm

(Sharecast News) - Cell-based therapeutics company ReNeuron Group announced on Thursday that it has signed a new research evaluation agreement with a major United States biotechnology company, in connection with the use of its proprietary exosomes for the delivery of novel gene silencing therapeutics.

Read more
17 Jun 2020 15:58

IN BRIEF: ReNeuron Gets Approval In US And UK For Expanded Drug Trial

IN BRIEF: ReNeuron Gets Approval In US And UK For Expanded Drug Trial

Read more
3 Apr 2020 11:41

UK TRADING UPDATE SUMMARY: Bagir Says Cash Insufficient To Carry On

UK TRADING UPDATE SUMMARY: Bagir Says Cash Insufficient To Carry On

Read more
24 Feb 2020 12:24

Positive hRPC Stem Cell Trial Data Prompts ReNeuron To Expand Study

Positive hRPC Stem Cell Trial Data Prompts ReNeuron To Expand Study

Read more
17 Feb 2020 10:29

Data From ReNeuron CTX Stem Cell Therapy Trial Published In Journal

Data From ReNeuron CTX Stem Cell Therapy Trial Published In Journal

Read more
18 Dec 2019 19:08

Woodford Transfers Series Of Holdings To New Manager Schroders

Woodford Transfers Series Of Holdings To New Manager Schroders

Read more
6 Dec 2019 10:42

ReNeuron cuts losses after Fosun licence payment

(Sharecast News) - ReNeuron Group on Friday reported a narrower interim loss after receiving payment from a Chinese licensee, while it also made progress in its clinical and research programmes.

Read more
6 Dec 2019 09:32

ReNeuron Reports "Strong Progress" Across Various Programmes

ReNeuron Reports "Strong Progress" Across Various Programmes

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.